Recent developments showcase advancements in diagnostic platforms and candidate therapies for cancer and rare diseases. Wholomics introduced a metabolomic cancer detection assay sensitive across multiple tumor types using nuclear magnetic resonance-based serum analysis, including early pancreatic cancer detection. Plus Therapeutics is relaunching the CNSide cerebrospinal fluid assay in the US for diagnosing and monitoring central nervous system metastases, employing ICC and FISH techniques. Qiagen expanded its clinical digital PCR menu through partnerships for assay development, complementing its QiAcuityDx system. Collectively, these innovations improve early detection and precision treatment strategies.